• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22754 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (non-transfusion-dependent beta-thalassaemia) - Addendum to Commission A23-20]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (treatment-resistant major depressive disorder) – Addendum to Commission A23-18]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) - Addendum to Commission A23-21]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (prurigo nodularis) – Addendum to Project A23-24]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (malignant biliary tract cancer [BTC]) – Addendum to Commission A23-26]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of invitation letters and information for insured persons on colorectal cancer screening]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis, 1 to < 2 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (cholangiocarcinoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (acute myeloid leukaemia, IDH1 R132 mutation, first line, combination with azacitidine) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fidanacogene elaparvovec (haemophilia B); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: resuscitation in community opioid overdose ‒ update and complement to INESSS guidance published in 2018 - Cardiopulmonary resuscitation (CPR) in a context of community-based naloxone administration for opioid overdose]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organizational models for the management of spinal cord injuries]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: benchmarks to improve services for at-risk or neglected children and their families]
2023     NIHR Health Technology Assessment programme Extracorporeal carbon dioxide removal compared to ventilation alone in patients with acute hypoxaemic respiratory failure: cost-utility analysis of the REST RCT
2023     NIHR Health Services and Delivery Research programme Understanding what affects psychological morbidity in informal carers when providing care at home for patients at the end of life: a systematic qualitative evidence synthesis
2023     NIHR Health Technology Assessment programme Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials
2023     NIHR Health Technology Assessment programme Antidepressants in pregnancy: applying causal epidemiological methods to understand service-use outcomes in women and long-term neurodevelopmental outcomes in exposed children
2023     NIHR Health Technology Assessment programme Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis
2023     NIHR Health Technology Assessment programme Helping pregnant smokers quit: a multi-centre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy
2023     NIHR Health Technology Assessment programme A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma – the ASCOT study
2023     NIHR Health Technology Assessment programme Frenotomy with breastfeeding support versus breastfeeding support alone for infants with tongue-tie and breastfeeding difficulties: the FROSTTIE RCT
2023     NIHR Health Services and Delivery Research programme Vertical integration of general practices with acute hospitals in England: rapid impact evaluation
2023     NIHR Health Services and Delivery Research programme Integration, effectiveness and costs of different models of primary health care provision for people who are homeless: an evaluation study
2023     NIHR Health Services and Delivery Research programme Explanation of context, mechanisms and outcomes in adult community mental health crisis care: the MH-CREST realist evidence synthesis
2023     Austrian Institute for Health Technology Assessment (AIHTA) Biomarkers in Alzheimer's disease
2023     NIHR Health Services and Delivery Research programme Identifying models of care to improve outcomes for older people with urgent care needs: a mixed methods approach to develop a system dynamics model
2023     NIHR Health Services and Delivery Research programme What happens after an NHS Health Check? A survey and realist review
2023     NIHR Health Services and Delivery Research programme A rapid mixed-methods evaluation of remote home monitoring models during the COVID-19 pandemic in England
2023     NIHR Health and Social Care Delivery Program Rapid evaluation of service innovations in health and social care: key considerations
2023     Andalusian Health Technology Assessment Area (AETSA) [Appropiate indication for leadless pacemaker. Systematic review and appropriateness criteria]
2023     Health Information and Quality Authority (HIQA) Rapid health technology assessment of continuous glucose monitoring in adults with type 1 diabetes mellitus
2023     Penn Medicine Center for Evidence-based Practice (CEP) Effectiveness of communication strategies for patients who are non-vocal due to artificial airways
2023     Institute for Clinical and Economic Review (ICER) Assessment of barriers to fair access
2023     Institute for Clinical and Economic Review (ICER) Advancing health technology assessment methods that support health equity
2023     Institute for Clinical and Economic Review (ICER) Applying the results of comparative effectiveness research to control drug costs: policy options for California
2023     Institute for Clinical and Economic Review (ICER) White bagging, brown bagging, and site of service policies: best practices in addressing provider markup in the commercial insurance market
2023     Institute for Clinical and Economic Review (ICER) ICER-PHTI assessment framework for digital health technologies
2023     Institute for Clinical and Economic Review (ICER) Value assessment framework
2023     Institute for Clinical and Economic Review (ICER) Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023     Institute for Clinical and Economic Review (ICER) Lecanemab for early Alzheimer’s disease
2023     Institute for Clinical and Economic Review (ICER) Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH)
2023     Institute for Clinical and Economic Review (ICER) Gene therapies for sickle cell disease: effectiveness and value
2023     Institute for Clinical and Economic Review (ICER) Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Dental bridges for partial tooth loss
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Optune - for the treatment of adult patients with newly diagnosed glioblastoma]
2023     WorkSafeBC Cold plunges as treatment for concussions
2023     WorkSafeBC Flotation therapy as treatment for concussions
2023     WorkSafeBC Efficacy of under-mask beard covers in quantitative fit testing of tight-fitting disposable respirators
2023     WorkSafeBC Causal association between COVID-19 infection and irritable larynx syndrome
2023     WorkSafeBC Migraines and the (Moderna) COVID-19 vaccine
2023     WorkSafeBC Botulinum toxin as treatment for neck strains
2023     WorkSafeBC Esketamine as treatment for depression and PTSD
2023     WorkSafeBC Platelet rich plasma in treating (recurrent) anterior shoulder dislocation
2023     WorkSafeBC Causal association between carpal tunnel release surgery and trigger finger
2023     WorkSafeBC Causal association between SARS-Cov-2 infection and the development of trigeminal neuralgia
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: models for coordinating interhospital transfers in critical care]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: asthma management in children and adults]
2023     Health Technology Wales (HTW) Control contact lenses and spectacles for the treatment of myopia in children
2023     Health Information and Quality Authority (HIQA) Methods for generic justification of new practices in ionising radiation
2023     Health Information and Quality Authority (HIQA) Analysis of public consultation surveys to inform the work of the Public Health Reform Expert Advisory Group [protocols and report]
2023     Health Information and Quality Authority (HIQA) Rapid health technology assessment of the extension of the seasonal influenza vaccination programme to include those aged 50 to 64 years (general population)
2023     NIHR Health Technology Assessment programme Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: implantable medical device tracking methods]
2023     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Speech-language therapy for laryngeal dysfunction]
2023     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Postoperative antimicrobial prophylaxis for thoracic surgery]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Economic dimensions of community nursing: A systematic literature review]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on advice for vitamin D substitution]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for gallbladder removal]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (ß-thalassaemia in patients ≥ 12 years); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) – Second Addendum to Commission A23-03]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (Bardet Biedl syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etranacogene dezaparvovec (haemophilia B) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tabelecleucel (relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), pretreated, 2 years and older) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (transfusion-dependent β-thalassaemia) - Assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure with LVEF > 40 %) – Addendum to Commission A23-11]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 3 and 4) – Addendum to Commission A23-15]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 1 and 2) – Addendum to Commission A23-14]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (previously untreated chronic lymphocytic leukaemia) – Addendum to Commission A23-04]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) – Addendum to Commission A23-06]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) – Addendum to Commission A23-07]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) – Addendum to Commission A23-03]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lutetium vipivotide tetraxetan (prostate cancer) – Addendum to Commission A23-01]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndrome) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn disease) – Addendum to Commission A22-133]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (primary open-angle glaucoma and ocular hypertension) – Addendum to Commission A22-129]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V]